top of page

WeCARe Project

This is a patient-centered outcomes study that captures the patient experience post-commercial CAR.

DEADLINE: Reach out to all living, English-speaking patients by May 1, 2025
ADDITIONAL ELIGIBILITY

  1. Pediatric and young adults with ALL who have previously undergone standard of care therapy with FDA approved immunotherapy, such as: Kymriah™ (CTL019, tisagenlecleucel)


  2. Age ≥ 0 and ≤26 years at time of immunotherapy treatment


  3. ≥1 month from time of infusion


  4. English or Spanish-speaking, living patients

COLLECTION

contact information of subject or proxy if ≤18 years

REQUIREMENTS

verbal agreement to share contact info with UAB

  • (UAB will consent subject with UAB ICF)

bottom of page